VAIA
ALLO icon

Virtus Alternative Investment Advisers’s Allogene Therapeutics ALLO Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-156
Closed -$4K – 9
2020
Q4 		$4K Sell
156
-151
-49% -$4.92K 0.06% 275
2020
Q3 		$12K Sell
307
-262
-46% -$9.88K 0.22% 45
2020
Q2 		$24K Sell
569
-532
-48% -$19.2K 0.37% 48
2020
Q1 		$21K Buy
1,101
+777
+240% +$18.5K 0.29% 180
2019
Q4 		$8K Buy
+324
New +$8.92K 0.12% 223

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Virtus Alternative Investment Advisers's ALLO Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 156 shares — an estimated $4K sold.

Virtus Alternative Investment Advisers first reported a position in ALLO in Q4 2019 and held it in 5 quarters. The position peaked at $24K in Q2 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 156 Allogene Therapeutics shares in Q1 2021, an estimated $4K.
  • Virtus Alternative Investment Advisers first reported a position in Allogene Therapeutics in Q4 2019 and held it in 5 quarters.
  • Virtus Alternative Investment Advisers's Allogene Therapeutics position peaked at $24K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.